Outer Biosciences (Outer Bio)
Category: AI in Biotech / Drug Discovery
AI + biotech startup that keeps donated full-thickness human skin alive for up to a month and uses machine learning on that living tissue to discover novel skincare/cosmetic ingredients. Outer Biosciences (Outer Bio) was founded in 2022. The company is led by Michael Polansky. Based in Mill Valley, California, USA. Team size: 11-50. Total funding raised: $23M. Latest round: Series A. Key investors include Wing Ventures, Initialized, Hawktail (Michael Polansky's firm), Calm Capital, Brighter Capital, Liquid 2 Ventures, Olive Capital, Gaingels.
- Founded
- 2022
- Headquarters
- Mill Valley, California, USA
- Team size
- 11-50
- Total funding
- $23M
Value proposition
Replaces poor proxies (animal models, cell cultures, organoids) with living full-thickness human skin kept viable for weeks, enabling AI to predict and validate novel skin-active ingredients on real human biology — generating a new candidate roughly every six weeks.
Products and solutions
YUNA discovery platform: full-thickness human skin viable for 4 weeks (epidermis, dermis, multiple resident cell types, preserved immune-associated molecular programs), multi-donor datasets across ages/races/genders/Fitzpatrick types, automated in vitro phenotype screening (robot liquid handling), ML models trained on proprietary human-tissue data that find novel targets and screen millions of compounds/day. Focus areas: anti-aging, anti-senescence, regeneration, barrier function, inflammation.
Unique value
Proprietary closed-loop system: living human tissue viable ~30 days (5x industry norm) + diverse donor pool + controlled experiments + repeated molecular measurements feeding an AI model that predicts beneficial compounds, with results fed back to improve predictions. Data is proprietary (no 'biology internet' to scrape), runs on-premise for data security.
Target customer
Biotech, pharma, skincare/cosmetics companies, and ingredient suppliers — licensing/selling finished cosmetic ingredients or running collaborative research partnerships (e.g., a pharma partner studying cancer-drug-induced skin rashes).
Industries served
Cosmetics/skincare ingredient discovery, biotech, pharma (dermatology, oncology supportive care), skin-health research
Technology advantage
Proprietary tissue-support system extending living full-thickness human skin viability to ~30 days (5x industry norm); closed-loop AI feedback system (predict → test on living tissue → feed results back); ML models trained exclusively on proprietary human-tissue data; on-premise AI for data security; multi-donor diversity across skin types.
How they differentiate
Unlike competitors growing synthetic organoids or using organ-on-a-chip, Outer Bio uses real donated full-thickness human skin kept alive for weeks, generating proprietary biological data that exists nowhere else. AI models are trained on its own human-tissue data rather than public datasets, and the closed feedback loop accelerates discovery from ~2 leads in 18 months (brute force) to a new candidate every ~6 weeks.
Main competitors
Vivodyne (Philadelphia — lab-grown human organ tissue + predictive AI), organ-on-a-chip / microphysiological systems companies (Emulate, MIMETAS, TissUse), traditional animal-model and cell-culture skin testing labs
Key partnerships
Tissue supply via National Disease Research Interchange and Cooperative Human Tissue Network (NIH/NCI-funded, IRB oversight, documented donor consent), collaboration with Haus Labs (Lady Gaga's cosmetics brand) — joint projects, chief scientist on Haus Labs' scientific advisory board, pharmaceutical partner studying cancer-drug-induced skin rashes
Notable customers
Haus Labs (Lady Gaga's cosmetics brand, collaborative partner), a pharmaceutical partner studying cancer-drug-induced skin rashes (collaborative research)
Major milestones
2022: Co-founded, 2022-2024: ~2 years building tissue pipeline/protocols, ~2024: raised Series A, Aug 2026: emerged from stealth with TechCrunch coverage, platform generating new candidate every ~6 weeks, 6 active leads (4 likely to reach commercialization), several dozen additional hits logged
Growth metrics
~19-22 employees; ~$23M raised; 6 active pipeline leads (4 likely to commercialize); new candidate generated every ~6 weeks; tissue viable ~30 days (5x industry norm)
Market positioning
Early-stage, stealth-emerged (Aug 2026) AI-driven skin bioactives discovery platform. Positioned as a defensible, data-moat player in a small market (~120-130 FDA-approved OTC skin drug actives; ~200 with research-backed cosmetics). Plans to license/sell ingredients rather than build a consumer brand.
Geographic focus
US (Mill Valley, CA HQ; R&D near Cambridge, MA); global cosmetics market with EU animal-testing ban as a demand driver
Patents and IP
Proprietary tissue-support system (feeds nutrients, removes metabolic waste, extends viable life to ~30 days); proprietary ML models trained on own human-tissue data; closed-loop discovery platform (IP not publicly detailed)
About Michael Polansky
Ex-Bridgewater Associates (3 years, investment); Ex-Founders Fund principal; Ran Sean Parker's family office (business/investment/philanthropy); Co-founder & Executive Director of Parker Institute for Cancer Immunotherapy. Harvard BA in Applied Mathematics & Computer Science (2006).
Latest news about Outer Biosciences (Outer Bio)
More AI in Biotech / Drug Discovery companies
Official website: https://www.outerbio.com/